Atherosclerosis: Lessons from LXR and the intestine

Barbara Bonamassa, Antonio Moschetta

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Modulation of the cholesterol-sensing liver X receptors (LXRs) and their downstream targets has emerged as promising therapeutic avenues in atherosclerosis. The intestine is important for its unique capabilities to act as a gatekeeper for cholesterol absorption and to participate in the process of cholesterol elimination in the feces and reverse cholesterol transport (RCT). Pharmacological and genetic intestine-specific LXR activation have been shown to protect against atherosclerosis. In this review we discuss the LXR-targeted molecular players in the enterocytes as well as the intestine-driven pathways contributing to cholesterol homeostasis with therapeutic potential as targets in the prevention and treatment of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)120-128
Number of pages9
JournalTrends in Endocrinology and Metabolism
Issue number3
StatePublished - Mar 2013


  • Atherosclerosis
  • High-density lipoprotein (HDL)
  • Intestine
  • Liver X receptors (LXRs)
  • Reverse cholesterol transport (RCT)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Atherosclerosis: Lessons from LXR and the intestine'. Together they form a unique fingerprint.

Cite this